Correlation between Expression of MVP, Index of p53 and AgNOR Value with Chemoradiotherapy Clinical Response of Cervical Cancer

Cervical cancer is the most frequent cancer found in Indonesia. The primary
treatment of cervical cancer at the locally advanced stage is usually performed by
using radiotherapy and chemotherapy. The combination of the two techniques is
often called chemoradioherapy. The response to chemoradiotherapy is influenced by
biological and physical factors. Major vault protein (MVP) is a ribonucleoprotein
which contributes to drug resistance in some cancers. The purposes of this research
were: (1) to determine the correlation between the expression of MVP and the index
of p53, including AgNOR values and index of MIB-1; and (2) between MVP and
chemoradiotherapy clinical response of cervical cancer. Twenty-one microscopic
slides taken from biopsy tissues of cervical cancer patients before undergoing
treatment were stained to identify MVP, p53, and MIB-1 by means of
immunohistochemistry techniques and AgNORs staining. After undergoing
chemoradiotherapy treatment, the patients’ clinical responses were observed by
pelvic control method. Experimental results showed that there was a correlation
between MVP and AgNOR value (P=0.05), but no correlation between MVP and
index of p53 (P=0.729), including MIB-1 LI (P=0.63), in untreated cervical cancer.
In addition, there was no association between MVP and chemoradioterapy response.
In conclusion, MVP expression correlates with the process of cell proliferation
before the G2 phase of cell cycle in untreated cancer cells. Those have no
association with clinical responses after the completion of treatment